- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Starpharma Holdings Limited (ASX:SPL,OTCQX:SPHRY) today announced it has appointed Malcolm McColl to join the company's existing business development team as a Vice President to meet the growing market demand for pharmaceutical and life science applications of Starpharma's dendrimer technology, particularly in drug delivery.
Malcolm is a seasoned business development professional with more than 20 years' experience with major biotechnology companies, including 13 years with CSL where he negotiated major agreements with Pfizer and Bayer, amongst many others. Malcolm joins Starpharma in August in the role of VP Business Development and will be supporting and enhancing Starpharma's already successful partnering activities and programs.
Malcolm returns to Australia from the UK where as Hospira's Business Development Director, Europe Middle East and Africa (EMEA), he was responsible for growing the global and EMEA business through an ambitious plan of targeted acquisitions and licensing activities. There he led negotiations and due diligence for a significant number of license agreements and transactions including Hospira's recent ~A$135M deal with Chemgenex for rights to Omacetaxine, a proprietary oncology product.
Dr Jackie Fairley, Chief Executive Officer of Starpharma, welcomed Malcolm to the executive team: "We are delighted to have Malcolm join Starpharma at this exciting stage of the company's development. His contribution will further enhance our already highly successful partnering activities in drug delivery, VivaGel®, in vitro diagnostics (IVD) and agrochemicals. Malcolm's international industry networks and experience will be a great asset in securing further commercial agreements and with this additional business development resource, Starpharma will significantly boost its commercial development capabilities."
Starpharma has established a successful business model of partnering with marketleading companies to maximise the value of its dendrimer platform in a range of industries and applications. The company has a growing list of major companies that are actively exploring the use of Starpharma's proprietary dendrimer technology to enhance the performance their pharmaceutical products, including Lilly, GSK, and in animal health, Elanco.
The company also has established commercial relationships with leading companies, such as SSL International plc, Siemens Healthcare, and EMD Merck KgA for other applications of its proprietary dendrimer technology.
Forward Looking Statements
This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "est mated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL’s dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
For more information, please click here
Mob: +61 417 382 391
Tel: +61 3 9866 4722
Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704
+61 3 8532 2702
Copyright © StarpharmaIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Graphene under pressure August 26th, 2016
Graphene under pressure August 26th, 2016